4
|
Want EJ, Coen M, Masson P, Keun HC, Pearce JTM, Reily MD, Robertson DG, Rohde CM, Holmes E, Lindon JC, Plumb RS, Nicholson JK. Ultra Performance Liquid Chromatography-Mass Spectrometry Profiling of Bile Acid Metabolites in Biofluids: Application to Experimental Toxicology Studies. Anal Chem 2010; 82:5282-9. [DOI: 10.1021/ac1007078] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Elizabeth J. Want
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Muireann Coen
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Perrine Masson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Hector C. Keun
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Jake T. M. Pearce
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Michael D. Reily
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Donald G. Robertson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Cynthia M. Rohde
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Elaine Holmes
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - John C. Lindon
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Robert S. Plumb
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Jeremy K. Nicholson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| |
Collapse
|
5
|
Ishihara K, Katsutani N, Asai N, Inomata A, Uemura Y, Suganuma A, Sawada K, Yokoi T, Aoki T. Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicity in rat model of cholestasis. Basic Clin Pharmacol Toxicol 2009; 105:156-66. [PMID: 19486331 DOI: 10.1111/j.1742-7843.2009.00410.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
This (1)H nuclear magnetic resonance metabonomics study was aimed to determine urinary biomarkers of cholestasis resulting from inhibition of biliary secretion of bile or obstruction of bile flow. To inhibit biliary secretion of bile, cyclosporine A was administered to male Sprague-Dawley rats. Obstruction of bile flow was induced by administration of 4,4'-methylene dianiline, alpha-naphthylisothiocyanate or bile duct ligation. Clinical pathological and histopathological examinations were performed to confirm cholestatic injury and (1)H nuclear magnetic resonance spectral data for urine samples were analysed to determine similarities and differences in profiles of metabolites using the Spotfire. In cyclosporine A-treated groups, serum total bilirubin and bile acid were significantly increased but no remarkable hepatic histopathological-changes were observed. In 4,4'-methylene dianiline-, alpha-naphthylisothiocyanate- and bile duct ligation-treated groups, serum alkaline phosphatase, gamma-glutamyltranspeptidase and total bilirubin levels increased significantly, and hepatic histopathological-changes were observed. On urinary (1)H nuclear magnetic resonance spectral analysis, area intensities derived from 0.66 to 1.90 ppm were decreased by cyclosporine A, whereas they were increased by other treatments. These metabolites were identified using the NMR suite as bile acids, branched-chain amino acids, n-butyrate, propionate, methyl malonate and valerate. These metabolites were further investigated by K-means clustering analysis. The cluster of these metabolites is considered to be altered by cholestasis. We conclude that bile acids, valine and methyl malonate have a possibility to be urinary cholestatic biomarkers, which distinguish a difference in mechanism of toxicity. (1)H nuclear magnetic resonance metabonomics thus appears to be useful for determining the mechanisms of toxicity and can be front-loaded in drug safety evaluation and biomarker discovery.
Collapse
Affiliation(s)
- Kenji Ishihara
- Tsukuba Research, Drug Safety Research Laboratories, Eisai Co, Ltd, Tsukuba, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|